Medical policy
Inflammatory Bowel Disease: Serologic Markers and Pharmacogenomic and Metabolic…
Aetna medical policy 0249
Key facts
| Policy title | Inflammatory Bowel Disease: Serologic Markers and Pharmacogenomic and Metabolic Assessment of Thiopurine Therapy |
|---|---|
| Insurer | Aetna |
| Policy number | 0249 |
| Current policy | Yes |
| Insurer page | aetna.com |
At a glance
- 1–9 510(k)s referenced
- None PMAs referenced
- None De Novos referenced
- 1–9 Clinical trials referenced
- 100–999 Articles referenced
- None UDI devices referenced
- None NDC products referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Insurer medical policies
Insurer clinical and medical policies state when a payer covers a device, drug or procedure. Orca1 links each policy to the FDA submissions, trials and articles it cites. Policy text is not reproduced here.
Source: Health insurer clinical and medical policies (insurer as listed); cross-links by Orca1